TheJakartaPost
Please Update your browser
Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.
Brazil greenlights human trials for J&J's potential COVID-19 vaccine
Change text size
Gift Premium Articles
to Anyone
Share the best of The Jakarta Post with friends, family, or colleagues. As a subscriber, you can gift 3 to 5 articles each month that anyone can read—no subscription needed!
Nurse Isabelli Guasso administers China's Sinovac vaccine, a potential vaccine for the coronavirus disease (COVID-19), to volunteer and nurse Fabiana Souza, at the Sao Lucas Hospital of the Pontifical Catholic University of Rio Grande do Sul (PUCRS), in Porto Alegre, Brazil August 8, 2020. (REUTERS/Diego Vara)
B
razil approved on Tuesday human clinical trials for a potential COVID-19 vaccine developed by Johnson & Johnson, the fourth candidate to trial in the Latin American country that has become key to the global race for a vaccine.
Health regulator Anvisa said it had given the green light to the study which will see 6,000 people in Brazil volunteer to trial the vaccine contender of Johnson & Johnson's pharmaceutical subsidiary Janssen.
With the world's biggest coronavirus outbreak outside the United States, Brazil has become a hub for mass clinical trials of potential vaccines.
Brazilian officials have vowed to start producing British and Chinese vaccines within a year, but experts warn it may take at least twice as long.
Brazil had registered 3.4 million cases of the disease caused by the novel coronavirus and more than 108,000 related deaths as of Monday.
Latin America's largest country has already approved phase 3 human trials of potential vaccines developed by AstraZeneca in partnership with the University of Oxford, China's Sinovac Biotech and Pfizer in partnership with BioNTech.
China's Sinopharm also aims to carry out trials for a possible vaccine in Brazil in a deal with the southern state of Parana pending regulatory approval.
Parana has signed a memorandum of understanding with Moscow and expects to produce a Russian vaccine, which controversially became the world's first registered coronavirus vaccine.
